Acuson's major emphasis will be on a new upgrade to the AcousticResponse Technology platform that was released in 1993. DubbedTissue Contrast Resolution (ART/TCR), the upgrade enhances theability of Acuson's 128 XP/10 scanners to differentiate
Acuson's major emphasis will be on a new upgrade to the AcousticResponse Technology platform that was released in 1993. DubbedTissue Contrast Resolution (ART/TCR), the upgrade enhances theability of Acuson's 128 XP/10 scanners to differentiate varioustypes of soft tissue (SCAN 11/9/95).
The ART upgrade improved the spatial and contrast resolutionof XP/10 scanners, but tissue differentiation remained a dilemmabecause tissues respond to ultrasound in different ways, accordingto Kerr Spencer, general imaging marketing manager of MountainView, CA-based Acuson. ART/TCR enables clinicians to see subtledifferences in tissue density and texture, Spencer said.
ART/TCR works with six Acuson transducers, two of which are newand will be debuted at the RSNA show: C7, a curved-array 7-MHzprobe, and L7T, a razor-shaped 7-MHz intraoperative transducer.Four existing probes support ART/TCR: V4, C3, V5M and V4C.
Acuson expects ART/TCR to find its greatest utility in gray-scaleimaging, although there should be improvements in image qualityusing the two new transducers in conjunction with the vendor'sColor Doppler Energy power Doppler mode.
ART/TCR will ship as an option on new XP/10 systems and willbe offered as an upgrade to XP/10 ART scanners in the field. Acusonexpects to begin shipping ART/TCR after the RSNA meeting.
In addition to the two new ART/TCR transducers, Acuson will displaytwo other new works-in-progress transducers: a 7-MHz probe forlaparoscopic surgical applications and a 7-MHz biplane endorectalprobe for prostate surgeries.
Acuson will also show enhancements to its Aegis ultrasound imagemanagement system. The company is improving its support for theACR-NEMA's DICOM 3.0 standard by developing a direct DICOM interface.Acuson is also developing an upgrade to be available in late 1996for its XP scanners that will allow new and installed XP scannersto be DICOM-compatible.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.